Aya Mohamed | MSc, MD 馃帡路 @Dr_Oncologista 路 X路路 2 days agoScore70
Body
ASTRIDE:馃珌
Serplulimab + chemotherapy showed a numerical OS advantage over atezolizumab + chemotherapy in 1L ES-SCLC (12.4 vs 10.2 months; HR 0.82).
@OncoAlert #ESMO26 #LungCancer #ESMOAmbassadors #Lcsm #ESMOcommunity @myESMO
51 views 路 5 likes 路 3 reposts 路 1 reply
Conference abstracts
Replies in this thread
- Aya Mohamed | MSc, MD 馃帡@Dr_Oncologista
@OncoAlert @myESMO 馃搳 Despite higher 2 year OS (32.2% vs 17.6%), the nearly identical PFS (HR 0.95) makes the survival signal difficult to interpret.
Source: Aya Mohamed | MSc, MD 馃帡 路 x.com